NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend alectinib (ALECENSA) as a treatment option for first-line ALK+ metastatic NSCLC (Category 1, Preferred). 4*†
*When an ALK rearrangement is discovered
prior to first-line systemic therapy.
†The NCCN Guidelines for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays.
1L PFS Results
View PFS results vs crizotinib from the head-to-head ALEX
CNS Efficacy in 1L ALK+ mNSCLC
Learn more about CNS efficacy with ALECENSA.
1L Safety Profile
Learn about the 1L safety profile with ALECENSA.